FDA Approves 2 New First-Line Treatments for Breast Cancer

Women fighting metastatic triple-negative breast cancer just got two new weapons in their corner, thanks to recent FDA approvals that could change how doctors treat this aggressive disease.

The FDA approved Datroway in May and Trodelvy in June as first-line treatments for metastatic TNBC. These are the first antibody-drug conjugates ever approved for this use, marking a major shift in how doctors can fight the disease from day one.

These drugs work like "smart chemo," delivering chemotherapy directly to cancer cells while leaving healthy cells alone. Regular chemotherapy attacks everything in its path, harming both cancerous and healthy tissue.

For many women with metastatic TNBC, chemotherapy has been the only option. Only about 30% of patients qualify for immunotherapy treatment with Keytruda because their tumors lack the right protein markers. That left the majority of women facing chemo as their sole choice.

Both new drugs target a protein called Trop-2, found on about 80% of breast cancer cells. They act like precision delivery trucks, carrying small amounts of chemotherapy directly to the cancer. Datroway and Trodelvy use different types of chemotherapy as their payload, giving doctors flexibility in treatment planning.

The results from clinical trials tell a powerful story. After about one year of treatment, both drugs reduced the risk of disease progression by around 40% compared to chemotherapy alone for patients ineligible for Keytruda. For women who could take Keytruda, adding Trodelvy reduced disease progression risk by 35%.

The Ripple Effect

This breakthrough reaches beyond treatment statistics. Ricki Fairley, cofounder of TOUCH, The Black Breast Cancer Alliance, captured the magnitude perfectly: scientists have been searching for alternatives to chemo-only treatment for over 20 years.

That two-decade quest just paid off for thousands of women. These approvals mean more treatment options, better outcomes, and hope where options were limited before. For families facing this diagnosis, having choices matters as much as the science itself.

The approval represents progress for one of the most challenging breast cancer types to treat. Triple-negative breast cancer doesn't respond to hormone therapy or targeted drugs that work for other breast cancer types, making effective treatment options especially precious.

Women diagnosed today have real alternatives their mothers and sisters didn't have just months ago.